High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F12%3A43901485" target="_blank" >RIV/00064173:_____/12:43901485 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11120/12:43901485
Výsledek na webu
<a href="http://dx.doi.org/10.1007/s11239-011-0659-5" target="_blank" >http://dx.doi.org/10.1007/s11239-011-0659-5</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s11239-011-0659-5" target="_blank" >10.1007/s11239-011-0659-5</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel
Popis výsledku v původním jazyce
According to recent trials, a significant number of patients do not have a completely effective response to clopidogrel. The aim of the study was to evaluate the rate of clopidogrel resistance in the context of important clinical characteristics and to specifically determine the relation between clopidogrel efficacy and biomarkers of inflammation. Consecutive non-selected patients following PCI were enrolled into the study. All patients received a loading dose of 600 mg of clopidogrel. The effect of clopidogrel was assessed using the VerifyNow assay 24 h after clopidogrel administration, clopidogrel resistance was defined as PRU 240. At the same time, standard parameters of biochemistry and hematology, the concentration of anti-inflammatory cytokine interleukin-10 and of soluble CD40 ligand, were measured. 378 patients were enrolled. 243 (64.3%) patients were responders (R) and 135 patients (35.7%) were non-responders (NR). Non-responders were older (R 65.7 - 13.3, NR 69.8- 11.5, P < 0
Název v anglickém jazyce
High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients treated with clopidogrel
Popis výsledku anglicky
According to recent trials, a significant number of patients do not have a completely effective response to clopidogrel. The aim of the study was to evaluate the rate of clopidogrel resistance in the context of important clinical characteristics and to specifically determine the relation between clopidogrel efficacy and biomarkers of inflammation. Consecutive non-selected patients following PCI were enrolled into the study. All patients received a loading dose of 600 mg of clopidogrel. The effect of clopidogrel was assessed using the VerifyNow assay 24 h after clopidogrel administration, clopidogrel resistance was defined as PRU 240. At the same time, standard parameters of biochemistry and hematology, the concentration of anti-inflammatory cytokine interleukin-10 and of soluble CD40 ligand, were measured. 378 patients were enrolled. 243 (64.3%) patients were responders (R) and 135 patients (35.7%) were non-responders (NR). Non-responders were older (R 65.7 - 13.3, NR 69.8- 11.5, P < 0
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FA - Kardiovaskulární nemoci včetně kardiochirurgie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/NS9988" target="_blank" >NS9988: Rezistence na protidestičkovou léčbu, její etiologie a možnosti ovlivnění.</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2012
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Journal of Thrombosis and Thrombolysis
ISSN
0929-5305
e-ISSN
—
Svazek periodika
33
Číslo periodika v rámci svazku
4, Spec. Iss. SI
Stát vydavatele periodika
NL - Nizozemsko
Počet stran výsledku
6
Strana od-do
349-354
Kód UT WoS článku
000303508600008
EID výsledku v databázi Scopus
—